Ubs Group Ag Cytokinetics Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, Ubs Group Ag holds 600 shares of CYTK stock, worth $29,916. This represents 0.0% of its overall portfolio holdings.

Number of Shares

600

Previous 299,604 99.8%

Holding current value

$29,916

Previous $16.2 Million 99.81%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $714,775 - $839,532	13,955 Added 4.66%	313,559 $16.6 Million
Q2 2024 Aug 13, 2024	BUY	$47.86 - $75.05 $41,159 - $64,543	860 Added 0.29%	299,604 $16.2 Million
Q1 2024 May 13, 2024	BUY	$63.75 - $108.06 $1.56 Million - $2.64 Million	24,436 Added 8.91%	298,744 $20.9 Million
Q4 2023 Feb 09, 2024	BUY	$26.88 - $83.49 $2.09 Million - $6.48 Million	77,637 Added 39.48%	274,308 $22.9 Million
Q3 2023 Nov 09, 2023	SELL	$29.46 - $36.61 $3.09 Million - $3.84 Million	-104,833 Reduced 34.77%	196,671 $5.79 Million
Q2 2023 Aug 11, 2023	BUY	$32.62 - $40.75 $1.67 Million - $2.09 Million	51,174 Added 20.44%	301,504 $9.84 Million
Q1 2023 May 12, 2023	SELL	$33.36 - $45.71 $2.83 Million - $3.88 Million	-84,887 Reduced 25.32%	250,330 $8.81 Million
Q4 2022 Feb 08, 2023	BUY	$35.77 - $51.11 $4.45 Million - $6.35 Million	124,320 Added 58.95%	335,217 $15.4 Million
Q3 2022 Nov 10, 2022	BUY	$38.54 - $54.52 $1.79 Million - $2.53 Million	46,415 Added 28.22%	210,897 $10.2 Million
Q2 2022 Aug 10, 2022	SELL	$33.93 - $48.92 $2.83 Million - $4.09 Million	-83,540 Reduced 33.68%	164,482 $6.46 Million
Q1 2022 May 16, 2022	BUY	$29.74 - $46.0 $108,521 - $167,854	3,649 Added 1.49%	248,022 $9.13 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $3.77 Million - $5.1 Million	109,869 Added 81.68%	244,373 $11.1 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $2 Million - $3.85 Million	107,854 Added 404.71%	134,504 $4.81 Million
Q2 2021 Aug 13, 2021	SELL	$19.79 - $26.99 $1.22 Million - $1.66 Million	-61,604 Reduced 69.8%	26,650 $528,000
Q1 2021 May 12, 2021	BUY	$18.57 - $25.68 $1.58 Million - $2.19 Million	85,091 Added 2690.2%	88,254 $2.05 Million
Q4 2020 Feb 11, 2021	BUY	$15.26 - $28.61 $9,949 - $18,653	652 Added 25.97%	3,163 $66,000
Q3 2020 Nov 12, 2020	BUY	$20.58 - $28.96 $3,272 - $4,604	159 Added 6.76%	2,511 $55,000
Q2 2020 Jul 31, 2020	SELL	$11.15 - $24.64 $199,997 - $441,967	-17,937 Reduced 88.41%	2,352 $55,000
Q1 2020 May 01, 2020	SELL	$8.75 - $16.3 $278,223 - $518,291	-31,797 Reduced 61.05%	20,289 $239,000
Q4 2019 Feb 14, 2020	SELL	$7.95 - $11.84 $359,936 - $536,056	-45,275 Reduced 46.5%	52,086 $552,000
Q3 2019 Nov 14, 2019	BUY	$10.82 - $14.25 $820,513 - $1.08 Million	75,833 Added 352.25%	97,361 $1.11 Million
Q2 2019 Aug 14, 2019	BUY	$7.95 - $11.25 $131,723 - $186,401	16,569 Added 334.12%	21,528 $242,000
Q1 2019 May 14, 2019	SELL	$5.95 - $10.19 $457,192 - $782,989	-76,839 Reduced 93.94%	4,959 $40,000
Q4 2018 Feb 14, 2019	BUY	$5.91 - $9.29 $442,422 - $695,449	74,860 Added 1078.99%	81,798 $517,000
Q3 2018 Nov 14, 2018	BUY	$6.4 - $9.85 $34,412 - $52,963	5,377 Added 344.46%	6,938 $68,000
Q2 2018 Aug 14, 2018	SELL	$6.9 - $9.9 $368,108 - $528,155	-53,349 Reduced 97.16%	1,561 $13,000
Q1 2018 May 15, 2018	BUY	$7.2 - $10.05 $274,356 - $382,955	38,105 Added 226.75%	54,910 $396,000
Q4 2017 Feb 14, 2018	SELL	$7.25 - $15.65 $58,340 - $125,935	-8,047 Reduced 32.38%	16,805 $137,000
Q3 2017 Nov 14, 2017	BUY	$12.0 - $15.0 $250,692 - $313,365	20,891 Added 527.42%	24,852 $361,000
Q2 2017 Aug 14, 2017	SELL	N/A	-10,320 Reduced 72.26%	3,961 $48,000
Q1 2017 Nov 14, 2017	BUY	N/A	14,281	14,281 $183,000

Others Institutions Holding CYTK

# of Institutions

410

Shares Held

125M

Call Options Held

4.6M

Put Options Held

2.43M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.69B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account